MapLight Therapeutics (MPLT) Other Accumulated Expenses (2024 - 2026)
MapLight Therapeutics (MPLT) posted Other Accumulated Expenses of $521000.0 for Q4 2025, down 75.54% sequentially from $2.1 million in Q3 2025, and down 66.56% YoY from $1.6 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Other Accumulated Expenses (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Other Accumulated Expenses for 2 years, with the latest figure at $521000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 66.56% year-over-year to $521000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $521000.0 (down 66.56% YoY) and the FY2025 annual result came in at $521000.0, down 66.56% from the prior year.
- Other Accumulated Expenses eased to $521000.0 in Q4 2025 per MPLT's latest filing, from $2.1 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $2.1 million in Q3 2025 and troughed at $521000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Dec 31, 2025 | 521,000.00 |
| Sep 30, 2025 | 2.13 Mn |
| Dec 31, 2024 | 1.56 Mn |